Organicell Regenerative Medicine

149 Bio, LLC is a Miami-based biotechnology company focused on developing innovative therapeutics for kidney diseases, with a particular emphasis on integrin activators. Their lead candidate, ONT01, is a clinical-stage oral small molecule integrin CD11b agonist aimed at treating lupus nephritis. The company utilizes its proprietary AI-enabled CellStaple Platform to identify novel antibody and small molecule therapeutics, positioning itself at the forefront of kidney disease treatment innovation. As AlloSite continues to expand, it seeks to grow its team to further advance its mission in the biopharmaceutical sector. Generated from the website

AEGLE Therapeutics is a pioneering clinical-stage developer of novel, cell-free therapies utilizing extracellular vesicles (EVs) to deliver a natural biomolecular payload for the treatment of debilitating rare diseases, including dystrophic epidermolysis bullosa (DEB) and severe dermatological disorders. With their proprietary EV harvesting technology, AEGLE Therapeutics harnesses the regenerative, immunomodulatory, and anti-inflammatory potential of MSC-derived EVs, such as exosomes, to develop AGLE-102, a therapeutic composite that has shown promising results in improving wound healing and stimulating cell function.Generated from the website

Green Canyon Ventures LLC is a Miami-based company that specializes in providing investment opportunities in various industries. With a focus on strategic partnerships and growth potential, Green Canyon Ventures LLC aims to support and nurture businesses seeking to expand and thrive. Generated from their business information